Skip to main content

Originally published December 17, 2013 at 10:16 AM | Page modified December 19, 2013 at 9:40 AM

  • Share:
  • Comments ((0))
  • Print

Corrected version

Seattle biotech Acucela plans $125M IPO on Tokyo exchange

Acucela is developing treatments for eye diseases but is cutting staff after the loss of a collaboration deal and a research setback.

By Seattle Times business staff

No comments have been posted to this article.


Acucela, a Seattle biotechnology company developing treatments for eye diseases, plans an initial public offering of up to $125 million in shares that would be traded on the Tokyo Stock Exchange, a rare move for a U.S.-based company.

The company, which has no marketable products yet, reports it has been profitable but is cutting staff after the loss of a collaboration deal and a research setback.

Acucela aims “to treat and slow the progression of sight-threatening ophthalmic diseases” such as age-related macular degeneration and diabetic macular edema, according to a regulatory filing Tuesday.

For a U.S. company to go public in Tokyo “is a very rare occurrence,” said Justin Jacobson, an analyst with Renaissance Capital, which tracks initial public offerings. “So rare we do not have any precedents for this event in our IPO database.”

Tokyo’s IPO market has been strong in 2013 while biotech IPO returns in the U.S. have been lackluster, Jacobson added.

Six IPOs have raised more than $100 million in the Tokyo Stock Exchange so far this year. One $251 million technology offering, Broadleaf, yielded an 82 percent return, according to Renaissance Capital data.

Acucela’s shares would trade on the so-called Mothers market of the Tokyo exchange, a market started in 1999 to attract listings from early-stage companies.

Founded in 2002, Acucela had revenue of nearly $42 million in the nine months ended Sept. 30, all from collaborations with Japanese pharmaceutical company Otsuka that began in 2008.

Otsuka also owns a 13 percent stake in Acucela.

Unlike the vast majority of early-stage biotech companies, Acucela reported a net profit — $5.1 million — in the latest nine months.

However, Otsuka in September terminated one co-development agreement with Acucela after a Phase 3 clinical trial of a drug called rebamipide for the treatment of dry-eye syndrome didn’t meet its primary goals.

The end of that agreement prompted Acucela to cut 35 percent of its workforce, or 30 people, this month.

Given the company’s reliance on Otsuka for funding its various programs, the IPO filing says “it would be difficult to replace Otsuka as a collaboration partner.”

Acucela was founded by ophthalmologist Ryo Kubota, who is president and CEO. He owns 44 percent of the company.

The other major stockholder is SBI Group of Japan, which owns 29 percent.

Seattle Times business reporter Ángel González contributed to this story.

Information in this article, originally published Dec. 17, 2013, was corrected Dec. 17. A previous version of this story incorrectly stated that SBI Group is an affiliate of Softbank. It was spun off from Softbank but is no longer affiliated.

News where, when and how you want it

Email Icon

 Subscribe today!

Subscribe today!

99¢ for four weeks of unlimited digital access.



The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited content access is included with most subscriptions.

Subscriber login ►